MYD88 and B-cell chronic lymphocytic leukemia: This is very well-exemplified by CLL, where studies have shown strong contradictions, both in the frequency of MYD88 mutations (from 1.5 to 10% of patients) [24,77] and in the prognostic significance: from favorable [78] to neutral [79] or unfavorable [80].